



2025 GNIPST BULLETIN

(Pharmacy)

Volume-2, Issue- 6



**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

1	Message from Director and Principal	1
2	Recent Researches	2
3	New Drug Approvals	3
4	Clinical Trial News	4
5	Disease Outbreak News	5
6	Campus News	6
7	Special Page	7
8	Game Time	8



MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my warmest greetings to all members of our academic family and well-wishers on the occasion of World Environment Day.

This day offers us a valuable opportunity to reflect on our responsibility towards the planet and renew our commitment to sustainability, innovation, and scientific excellence. At our esteemed institution, we

remain dedicated to nurturing inquisitive minds, fostering environmental consciousness, and empowering students to become future leaders in Pharmaceutical Sciences—with a vision for a healthier world and a greener future.

Let us move forward with renewed enthusiasm, a spirit of collaboration, and unwavering determination to contribute to global well-being and environmental stewardship.

Wishing you and your loved ones good health, peace, progress, and fulfillment in all your endeavours.

Prof. (Dr.) Abhijit Sengupta

MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to all our students, faculty, staff, alumni, and valued partners on the occasion of World Environment Day. May the days ahead bring peace, prosperity, good health, and a renewed commitment to environmental responsibility in all aspects of life. At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we remain deeply committed to academic

excellence, inclusive development, and sustainability. Since our establishment in 2005, GNIPST has grown into a distinguished institution in pharmacy education—recognized by the Pharmacy Council of India (PCI) and honored as the first pharmacy college in the region to receive both NAAC and NBA accreditations. Our 74th rank in NIRF 2024 further reflects our dedication to quality education and professional advancement.


As we continue our academic journey, we reaffirm our mission to nurture intellectual curiosity, promote innovation, and empower students to become not only leaders in pharmaceutical sciences but also responsible global citizens mindful of their impact on the environment.

At GNIPST, we take pride in fostering a culture that supports personal growth, leadership, and a strong commitment to societal and environmental well-being.

Let us all move forward with integrity, passion, and a shared sense of purpose—working together for a healthier planet and a sustainable future.

Wishing you all continued success, fulfillment, and meaningful achievements on this important day and beyond.

Prof. (Dr.) Lopamudra Datta





African Union and World Health Organization renew strategic partnership to drive impact and strengthen health systems in Africa

MORE INFO

www.who.int/



WHO Results Report 2024 shows health progress across regions overcoming critical challenges

MORE INFO

www.who.int/

RECENT RESEARCHES



The World Health Organization (WHO) [Results Report 2024](#), shows progress on global health goals, even in times of growing financial uncertainties. The report, released ahead of the [Seventy-eight World Health Assembly](#) (19–27 May 2025), presents a mid-term assessment of WHO's performance in implementing the Programme budget 2024–2025, providing a snapshot of progress towards the strategic priorities of the Thirteenth General Programme of Work, 2019–2025. The report highlights WHO's work in over 150 countries, territories and provides an update on the implementation of the Thirteenth General Programme of Work, showcasing both the achievements so far and challenges ahead.

The World Health Organization (WHO) has validated Mauritania as having eliminated trachoma as a public health problem, making it the seventh country in WHO's African Region to achieve this significant milestone. The validation certificate was received by Honorable Abdallahi Sidi Mohamed Wedih, Minister of Health and Aïcha Vall Vergès, Ambassador of Mauritania to Switzerland at the Seventy-eighth World Health Assembly.

The World Health Organization (WHO) and the African Union (AU) Commission renewed their longstanding strategic partnership today with the signing of an updated Memorandum of Understanding (MoU) on the sidelines of the 78th World Health Assembly in Geneva. This renewed agreement reaffirms the joint commitment to advancing health security, universal health coverage, and sustainable development across the African continent at a time of unprecedented financial challenges in the global health landscape. It further underscores the African Union's leadership in fostering collective action, inclusive partnerships, and regional resilience, and positions the Department of Health, Humanitarian Affairs, and Social Development of the AU Commission at the heart of the continent's health policy implementation efforts. The agreement was signed by Her Excellency Ambassador Amma Adomaa Twum-Amoah, Commissioner for Health, Humanitarian Affairs and Social Development, on behalf of His Excellency Mahmoud Ali Youssouf, Chairperson of the African Union Commission, and Dr Tedros Adhanom Ghebreyesus, WHO Director-General. It marks a defining moment for primary health care and universal health coverage.





NEW DRUG APPROVALS

May, 2025

Brekiya (dihydroergotamine mesylate) Injection

- Company: Amneal Pharmaceuticals LLC
- Date of Approval: May 14, 2025
- Treatment for: Migraine, Cluster Headaches



Nuvaxovid (COVID-19 Vaccine, Adjuvanted) Injectable Suspension – formerly Novavax COVID-19 Vaccine

- Company: Novavax, Inc.
- Date of Approval: May 16, 2025
- Treatment for: COVID-19



Yutrepla (treprostinil) Inhalation Powder – formerly LIQ861

- Company: Liquidia Technologies, Inc.
- Date of Approval: May 23, 2025
- Treatment for: Pulmonary Arterial Hypertension; Pulmonary Hypertension Associated with Interstitial Lung Disease



mNEXSPIKE (COVID-19 Vaccine, mRNA) Injection

- Company: Moderna, Inc.
- Date of Approval: May 30, 2025
- Treatment for: COVID-19



Emrelis (telisotuzumab vedotin-tllv) Lyophilized Powder for Injection – formerly Teliso-V

- Company: AbbVie Inc.
- Date of Approval: May 14, 2025
- Treatment for: Non Small Cell Lung Cancer



Starjemyza (ustekinumab-hmny) Injection

- Company: Bio-Thera Solutions, Ltd.
- Date of Approval: May 22, 2025
- Treatment for: Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis



Khindivi (hydrocortisone) Oral Solution – formerly ET-400

- Company: Eton Pharmaceuticals, Inc.
- Date of Approval: May 28, 2025
- Treatment for: Adrenocortical Insufficiency



<https://www.drugs.com/newdrugs.html>





CLINICAL TRIAL NEWS



01.

HHS, NIH Launch Next-Generation Universal Vaccine Platform for Pandemic-Prone Viruses

The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform. This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH's in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910.

02.

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy.

03.

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT).

04.

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial of Efruxifermin in the New England Journal of Medicine

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publication of results from the Phase 2b SYMMETRY trial in the New England Journal of Medicine.

05.

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment.

06.

Arvinas and Pfizer's Vepdugestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdugestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy.

MORE INFORMATION



https://www.drugs.com/clinical_trials_archive/january-2025.html



DISEASE OUTBREAK NEWS (DONS)

May, 2025

Anthrax - Thailand

29 May 2025

Situation at a glance

In early May 2025, the International Health Regulations National Focal Point (IHR NFP) for Thailand notified WHO of four cases of cutaneous anthrax. One of the affected individuals died as a result of disease complications, while the remaining three cases were hospitalized and received appropriate medical care. All reported cases had direct contact with cattle suspected to be infected with anthrax. A rapid field investigation and response was conducted by the national health authorities. All potentially exposed individuals were identified, and all high-risk contacts received post-exposure prophylaxis. On 28 May, an additional case was announced who was associated with the slaughtering of cattle. Disease control measures, including animal quarantine, and vaccination campaign targeting cattle within five km radius, public awareness campaigns, and enhanced surveillance, were implemented in the affected area. Anthrax is a life-threatening zoonotic disease caused by the spore-forming bacterium *Bacillus anthracis*. Humans can get anthrax from infected animals or contaminated animal products. It generally does not spread between people. Currently, due to the robust public health measures implemented by Thailand, the risk of international disease spread through animal movement remains low.



MORE
INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573>

Yellow fever - Region of the Americas

Situation at a glance 26 April, 2025

From 29 December 2024 and as of 26 April 2025 (with data for Ecuador updated as of 2 May 2025), a total of 212 confirmed human cases of yellow fever, including 85 deaths, have been reported to WHO by five countries in the Region of the Americas (case fatality rate (CFR) 40%). The cases have been reported in the Plurinational State of Bolivia, Brazil, Colombia, Ecuador and Peru. The 212 confirmed yellow fever cases reported so far in 2025 represent a threefold increase compared to the 61 confirmed cases reported in 2024. WHO is supporting affected countries in implementing coordinated actions to respond to the yellow fever cases and outbreaks. This includes enhancing preventive measures, strengthening surveillance and case management, improving risk communication and community engagement, and implementing immunization activities. The current yellow fever situation in the Americas is driven by increased sylvatic transmission cycles. The occurrence of yellow fever cases outside of the Amazon basin, combined with high fatality, varying vaccination coverage across affected countries, and limited vaccine supply, contributes to the overall classification of yellow fever risk in the Region of the Americas, especially in endemic countries, as high. WHO emphasizes the importance of active surveillance, timely laboratory testing, cross-border coordination, and information sharing. Vaccination remains the primary means for the prevention and control of yellow fever. WHO continues to support countries in expanding vaccination coverage through routine immunization programs and mass vaccination campaigns to enhance population immunity and reduce the risk of outbreaks.



MORE
INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>




CAMPUS NEWS



1. On- Campus Employment Drive: GNIPST organized a Placement Drive for TATA 1mg on June 3, 2025, exclusively for D.Pharm and B.Pharm students of the 2024 and 2025 batches.



2. Five Days Faculty development Program: GNIPST organized a 5-Day Faculty Development Program (FDP) from June 11–15, 2025 in hybrid mode on the theme: “**Implementations and Applications of Biotechnology in Pharmaceutical Industry and Environment.**” This FDP aims to enhance knowledge and practical insights into cutting-edge biotechnological approaches relevant to pharma and environmental sustainability.



MORE INFORMATION ➔

www.gnipst.ac.in



World Environment Day: A Global Call for Environmental Protection


World Environment Day, celebrated every year on June 5, is the United Nations' principal vehicle for encouraging global awareness and action for the protection of our environment. First held in 1974, this day highlights critical environmental issues such as pollution, biodiversity loss, and climate change. Each year, it is hosted by a different country and centers around a unique theme to drive focused efforts and positive change.

Significance:

- Raises awareness about urgent environmental challenges globally.
- Encourages individual and collective action to protect nature.
- Promotes sustainable practices in industries, schools, and communities.
- Provides a platform for governments and NGOs to share policies and solutions.
- Inspires youth and future generations to take responsibility for the planet.
- Fosters international cooperation for environmental restoration and conservation.
- Reinforces the idea that “Only One Earth” must be nurtured and protected.



GNIPST GAME TIME



THE DRUG NAME EMOJI GAME

1.  -is- 
2.  - 
3.  -U- 
4.  -CO- 
5.  -  - 

Stay tuned for the next edition for a shout out to fastest correct answers!

Submit your answer



or

CLICK
HERE

Cheers to the Victor!

Volume -2, Issue -5



Shaswati Ghosh
B.Pharm, 4th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology



Editorial Board

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major Recruiters

Latest news



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com